The anthracycline metabolite doxorubicinol abolishes ryr2 sensitivity to physiological changes in luminal Ca21 through an interaction with calsequestrin

Amy D. Hanna, Alexander Lam, Chris Thekkedam, Hermia Willemse, Angela F. Dulhunty, Nicole A. Beard

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

The chemotherapeutic anthracycline metabolite doxorubicinol (doxOL) has been shown to interact with and disrupt the function of the cardiac ryanodine receptor Ca21 release channel (RyR2) in the sarcoplasmic reticulum (SR) membrane and the SR Ca21 binding protein calsequestrin 2 (CSQ2). Normal increases in RyR2 activity in response to increasing diastolic SR [Ca21] are influenced by CSQ2 and are disrupted in arrhythmic conditions. Therefore, we explored the action of doxOL on RyR2’s response to changes in luminal [Ca21] seen during diastole. DoxOL abolished the increase in RyR2 activity when luminal Ca21 was increased from 0.1 to 1.5 mM. This was not due to RyR2 oxidation, but depended entirely on the presence of CSQ2 in the RyR2 complex. DoxOL binding to CSQ2 reduced both the Ca21 binding capacity of CSQ2 (by 48%–58%) and its aggregation, and lowered CSQ2 association with the RyR2 complex by 67%–77%. Each of these effects on CSQ2, and the lost RyR2 response to changes in luminal [Ca21], was duplicated by exposing native RyR2 channels to subphysio-logic (#1.0 mM) luminal [Ca21]. We suggest that doxOL and low luminal Ca21 both disrupt the CSQ2 polymer, and that the association of the monomeric protein with the RyR2 complex shifts the increase in RyR2 activity with increasing luminal [Ca21] away from the physiologic [Ca21] range. Subsequently, these changes may render the channel insensitive to changes of luminal Ca21 that occur through the cardiac cycle. The altered interactions between CSQ2, triadin, and/or junctin and RyR2 may produce an arrhythmogenic substrate in anthracycline-induced cardiotoxicity.

Original languageEnglish
Pages (from-to)576-587
Number of pages12
JournalMolecular Pharmacology
Volume92
Issue number5
DOIs
Publication statusPublished - 1 Nov 2017

Fingerprint

Calsequestrin
Ryanodine Receptor Calcium Release Channel
Anthracyclines
Sarcoplasmic Reticulum
adriamycinol
Diastole

Cite this

Hanna, Amy D. ; Lam, Alexander ; Thekkedam, Chris ; Willemse, Hermia ; Dulhunty, Angela F. ; Beard, Nicole A. / The anthracycline metabolite doxorubicinol abolishes ryr2 sensitivity to physiological changes in luminal Ca21 through an interaction with calsequestrin. In: Molecular Pharmacology. 2017 ; Vol. 92, No. 5. pp. 576-587.
@article{f60dfbdefccc4625a2479462393f82f3,
title = "The anthracycline metabolite doxorubicinol abolishes ryr2 sensitivity to physiological changes in luminal Ca21 through an interaction with calsequestrin",
abstract = "The chemotherapeutic anthracycline metabolite doxorubicinol (doxOL) has been shown to interact with and disrupt the function of the cardiac ryanodine receptor Ca21 release channel (RyR2) in the sarcoplasmic reticulum (SR) membrane and the SR Ca21 binding protein calsequestrin 2 (CSQ2). Normal increases in RyR2 activity in response to increasing diastolic SR [Ca21] are influenced by CSQ2 and are disrupted in arrhythmic conditions. Therefore, we explored the action of doxOL on RyR2’s response to changes in luminal [Ca21] seen during diastole. DoxOL abolished the increase in RyR2 activity when luminal Ca21 was increased from 0.1 to 1.5 mM. This was not due to RyR2 oxidation, but depended entirely on the presence of CSQ2 in the RyR2 complex. DoxOL binding to CSQ2 reduced both the Ca21 binding capacity of CSQ2 (by 48{\%}–58{\%}) and its aggregation, and lowered CSQ2 association with the RyR2 complex by 67{\%}–77{\%}. Each of these effects on CSQ2, and the lost RyR2 response to changes in luminal [Ca21], was duplicated by exposing native RyR2 channels to subphysio-logic (#1.0 mM) luminal [Ca21]. We suggest that doxOL and low luminal Ca21 both disrupt the CSQ2 polymer, and that the association of the monomeric protein with the RyR2 complex shifts the increase in RyR2 activity with increasing luminal [Ca21] away from the physiologic [Ca21] range. Subsequently, these changes may render the channel insensitive to changes of luminal Ca21 that occur through the cardiac cycle. The altered interactions between CSQ2, triadin, and/or junctin and RyR2 may produce an arrhythmogenic substrate in anthracycline-induced cardiotoxicity.",
keywords = "RyR2, ryanodine receptor, chemotherapeutic anthracycline metabolite, doxorubicinol",
author = "Hanna, {Amy D.} and Alexander Lam and Chris Thekkedam and Hermia Willemse and Dulhunty, {Angela F.} and Beard, {Nicole A.}",
year = "2017",
month = "11",
day = "1",
doi = "10.1124/mol.117.108183",
language = "English",
volume = "92",
pages = "576--587",
journal = "Molecular Pharmacology",
issn = "0026-895X",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "5",

}

The anthracycline metabolite doxorubicinol abolishes ryr2 sensitivity to physiological changes in luminal Ca21 through an interaction with calsequestrin. / Hanna, Amy D.; Lam, Alexander; Thekkedam, Chris; Willemse, Hermia; Dulhunty, Angela F.; Beard, Nicole A.

In: Molecular Pharmacology, Vol. 92, No. 5, 01.11.2017, p. 576-587.

Research output: Contribution to journalArticle

TY - JOUR

T1 - The anthracycline metabolite doxorubicinol abolishes ryr2 sensitivity to physiological changes in luminal Ca21 through an interaction with calsequestrin

AU - Hanna, Amy D.

AU - Lam, Alexander

AU - Thekkedam, Chris

AU - Willemse, Hermia

AU - Dulhunty, Angela F.

AU - Beard, Nicole A.

PY - 2017/11/1

Y1 - 2017/11/1

N2 - The chemotherapeutic anthracycline metabolite doxorubicinol (doxOL) has been shown to interact with and disrupt the function of the cardiac ryanodine receptor Ca21 release channel (RyR2) in the sarcoplasmic reticulum (SR) membrane and the SR Ca21 binding protein calsequestrin 2 (CSQ2). Normal increases in RyR2 activity in response to increasing diastolic SR [Ca21] are influenced by CSQ2 and are disrupted in arrhythmic conditions. Therefore, we explored the action of doxOL on RyR2’s response to changes in luminal [Ca21] seen during diastole. DoxOL abolished the increase in RyR2 activity when luminal Ca21 was increased from 0.1 to 1.5 mM. This was not due to RyR2 oxidation, but depended entirely on the presence of CSQ2 in the RyR2 complex. DoxOL binding to CSQ2 reduced both the Ca21 binding capacity of CSQ2 (by 48%–58%) and its aggregation, and lowered CSQ2 association with the RyR2 complex by 67%–77%. Each of these effects on CSQ2, and the lost RyR2 response to changes in luminal [Ca21], was duplicated by exposing native RyR2 channels to subphysio-logic (#1.0 mM) luminal [Ca21]. We suggest that doxOL and low luminal Ca21 both disrupt the CSQ2 polymer, and that the association of the monomeric protein with the RyR2 complex shifts the increase in RyR2 activity with increasing luminal [Ca21] away from the physiologic [Ca21] range. Subsequently, these changes may render the channel insensitive to changes of luminal Ca21 that occur through the cardiac cycle. The altered interactions between CSQ2, triadin, and/or junctin and RyR2 may produce an arrhythmogenic substrate in anthracycline-induced cardiotoxicity.

AB - The chemotherapeutic anthracycline metabolite doxorubicinol (doxOL) has been shown to interact with and disrupt the function of the cardiac ryanodine receptor Ca21 release channel (RyR2) in the sarcoplasmic reticulum (SR) membrane and the SR Ca21 binding protein calsequestrin 2 (CSQ2). Normal increases in RyR2 activity in response to increasing diastolic SR [Ca21] are influenced by CSQ2 and are disrupted in arrhythmic conditions. Therefore, we explored the action of doxOL on RyR2’s response to changes in luminal [Ca21] seen during diastole. DoxOL abolished the increase in RyR2 activity when luminal Ca21 was increased from 0.1 to 1.5 mM. This was not due to RyR2 oxidation, but depended entirely on the presence of CSQ2 in the RyR2 complex. DoxOL binding to CSQ2 reduced both the Ca21 binding capacity of CSQ2 (by 48%–58%) and its aggregation, and lowered CSQ2 association with the RyR2 complex by 67%–77%. Each of these effects on CSQ2, and the lost RyR2 response to changes in luminal [Ca21], was duplicated by exposing native RyR2 channels to subphysio-logic (#1.0 mM) luminal [Ca21]. We suggest that doxOL and low luminal Ca21 both disrupt the CSQ2 polymer, and that the association of the monomeric protein with the RyR2 complex shifts the increase in RyR2 activity with increasing luminal [Ca21] away from the physiologic [Ca21] range. Subsequently, these changes may render the channel insensitive to changes of luminal Ca21 that occur through the cardiac cycle. The altered interactions between CSQ2, triadin, and/or junctin and RyR2 may produce an arrhythmogenic substrate in anthracycline-induced cardiotoxicity.

KW - RyR2

KW - ryanodine receptor

KW - chemotherapeutic anthracycline metabolite

KW - doxorubicinol

UR - http://www.scopus.com/inward/record.url?scp=85031800515&partnerID=8YFLogxK

UR - http://www.mendeley.com/research/dmd-108183

U2 - 10.1124/mol.117.108183

DO - 10.1124/mol.117.108183

M3 - Article

VL - 92

SP - 576

EP - 587

JO - Molecular Pharmacology

JF - Molecular Pharmacology

SN - 0026-895X

IS - 5

ER -